Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

This study is testing a low-dose, continuous combination of three chemotherapy drugs — trabectedin, gemcitabine, and dacarbazine — in patients with an advanced soft tissue cancer called leiomyosarcoma that has already been treated with at least one prior therapy. **You may be eligible if...** - You are 18 or older - You have been diagnosed with locally advanced, unresectable, or metastatic leiomyosarcoma (a type of smooth muscle cancer) - You have already received at least one prior treatment for this cancer - Your disease is measurable on scans - Your heart, liver, kidneys, and blood counts are functioning adequately - Your overall health is reasonable (ECOG score 0–2) **You may NOT be eligible if...** - You have not previously received any treatment for this cancer - Your liver, kidney, or blood counts are significantly abnormal - You have significant heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.